165 - Anatomy of a Target Product Profile(TPP): All 10 Sections EXPLAINED with Marta New

165 - Anatomy of a Target Product Profile(TPP): All 10 Sections EXPLAINED with Marta New

In this episode of Let's Combinate, host Subhi Sadeh is joined by Marta New, CEO of Radyus Research, to discuss the importance of Target Product Profiles (TPPs) in drug development and combination products. Marta, with her unique background as a venture capitalist turned CRO founder, shares her insights on how TPPs serve as strategic documents that align clinical goals, regulatory requirements, and market strategies. The discussion delves into the key sections of a TPP, such as target indication, efficacy benchmarks, safety and toxicology, and regulatory strategy. Marta emphasizes the critical role of TPPs in preclinical stages and their impact on the overall success of drug development programs. The episode also explores the integration and collaboration required across various functions like R&D, quality, regulatory, and commercial teams to create and refine a robust TPP.


00:00 Introduction and Welcome

00:26 Meet Marta: CEO of Radius Research

00:58 Understanding Target Product Profiles (TPPs)

01:44 The Importance of TPPs in Drug Development

01:59 Defining a TPP

03:22 TPP as a Strategic Document

05:28 TPP in Preclinical and Clinical Stages

07:09 Challenges and Misconceptions in TPP Development

14:27 Regulatory Considerations for TPPs

14:53 Sections of a TPP

39:07 Understanding Toxicology Evaluations

39:34 FDA Requirements for Pre-IND Talks

39:51 TPP and Toxicity Thresholds

41:41 Go/No-Go Criteria in TPP

42:50 PKPD and Drug Distribution

45:40 Drug Formulation and Quality Attributes

46:36 Regulatory Strategy and 505(b)(2) Pathway

52:34 Differentiation and Risk Assessment

01:03:42 Transition from Discovery to Development

01:07:48 Combination Products and Delivery Systems

01:09:35 Conclusion and Contact Information


Marta New PhD MBA is the CEO of Radyus Research. She is an experienced drug developer with a background in early-stage venture capital, considerable pharma R&D, and university technology transfer. She can be reached at mnew@radyusresearch.com

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(247)

240 - ICH Q13: Continuous Manufacturing, Batches, Residence Time Distribution and Control Strategy

240 - ICH Q13: Continuous Manufacturing, Batches, Residence Time Distribution and Control Strategy

ICH Q13 explains how pharmaceutical companies can apply batch definition, traceability, control strategy, validation, release, and lifecycle management to continuous manufacturing of drug substances a...

3 Kesä 11min

239 - ICH Q12: What’s Binding? Established Conditions and Post-Approval Changes

239 - ICH Q12: What’s Binding? Established Conditions and Post-Approval Changes

In this episode, Subhi breaks down ICH Q12, the guideline focused on post-approval change management and pharmaceutical product lifecycle management.The core question behind ICH Q12 is simple: once a ...

27 Touko 10min

239 - ICH Q11 in 6 Minutes

239 - ICH Q11 in 6 Minutes

In this episode, Subhi breaks down Q11 by focusing on three key sections: how the drug substance process is developed, where that process begins, and how it is controlled.He places Q11 in context with...

20 Touko 6min

238 - 6 Audit Strategies Every Auditor Should Know

238 - 6 Audit Strategies Every Auditor Should Know

Six Major Auditing Strategies: Tracing, Process, Department, Element, Process-Based Management, and DiscoveryCourse Link: https://cqeacademy.teachable.com/p/the-cqa-master-class-courseIn this episode,...

13 Touko 10min

237 - ICH Q10: The Pharmaceutical Quality System

237 - ICH Q10: The Pharmaceutical Quality System

his episode looks at where Q10 fits in the broader quality landscape, including its roots in ISO 9001, ISO 9004, and ISO 13485, while making the key distinction that Q10 is not a certifiable ISO-style...

6 Touko 8min

236: ICH Q9: Quality Risk Management (QRM) + ISO 14971 Differences

236: ICH Q9: Quality Risk Management (QRM) + ISO 14971 Differences

ICH Q9 is one of the most referenced guidelines in pharma and one of the most misunderstood.In this video, I break down what Quality Risk Management (QRM) actually is, how the process works, and how i...

29 Huhti 12min

235 - ICH Q8: How Pharmaceutical Development Actually Works

235 - ICH Q8: How Pharmaceutical Development Actually Works

This episode continues the ICH Quality Series with an overview of ICH Q8 (Pharmaceutical Development), focusing on what it is, how it’s structured, and how to think about it in practice.ICH Q8 defines...

22 Huhti 10min

234 - ICH Q7: The GMP Framework for API Manufacturing

234 - ICH Q7: The GMP Framework for API Manufacturing

In this episode of Let’s Combinate, Subhi breaks down ICH Q7. Unlike topic-specific guidelines, Q7 covers the full GMP framework for API manufacturing. This episode walks through how to actually read ...

15 Huhti 13min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-hereilla
rss-poliisin-mieli
rss-duodecim-lehti
docemilia
radio-antro
filocast-filosofian-perusteet
rss-radplus
rss-totuuden-liepeilla
utelias-mieli
tiedekulma-podcast
rss-tiedetta-vai-tarinaa
rss-lihavuudesta-podcast
rss-kasvikutsut